„The strong results recorded in the first quarter of 2025 reflect the healthy development path the company is on, in a year of strategic significance for Norofert. In the upcoming period, we will mark the start of production at our Brazil facility, built on an operational model already successfully validated the USA. We recorded an EBITDA margin of over 50% at group level and revenues exceeding RON 1.2 million in the USA, results that confirm the effectiveness of our strategic decisions. Research and development remain central pillars of our sustainable growth. The laboratory in Filipeștii de Pădure, where we are developing our own microorganism strain bank, gives us a significant competitive edge in an everevolving industry. This innovation capacity enables us to tailor our product portfolio to the specific needs of each market. We are focused on strengthening our presence in the USA and Brazil—two strategic markets that have the potential to generate up to 40% of the Group’s turnover in the next three years,” stated Vlad Popescu, Norofert Board President.
The new investment in Chapeco – Brazil is expected to start generating revenues in the second half of the year. In 2025, the company estimates that the two factories on the American continent will generate approximately 7% of the Group’s total revenue.
The company in Q1 reported RON14.8 million operating revenues, up 16%, and RON7 million operating result, 8 times higher.
Norofert is valued by investors at RON54 million. Its shares have dropped by 12% since the start of the year amid RON4.5 million deals.
(English version by Catalina Apostoiu)